Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia

Schizophrenia Research

Volumn 143, Issue 2-3, 2013, Pages 344-347

  Gunduz Bruce, Handan ^a,b,c   Oliver, Stephen ^a   Gueorguieva, Ralitza ^d   Forselius Bielen, Kimberlee ^c   D'Souza, Deepak C ^a,b,c   Zimolo, Zoran ^a,b,c   Tek, Cenk ^a,c   Kaliora, Styliani ^e   Ray, Susan ^e   Petrides, Georgios ^e,f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine   (United States)

^d YALE UNIVERSITY   (United States)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Clozapine; Dopamine; Schizophrenia; Working memory

Indexed keywords

CLOZAPINE; PIMOZIDE; PLACEBO;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCARDIOGRAM; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; NERVOUS SYSTEM PARAMETERS; OUTPATIENT; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGIC TEST; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; VERBALIZATION; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIMOZIDE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84872423918     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.11.008     Document Type: Article

References (16)

1. Buckley P., Miller A., Olsen J., Garver D., Miller D.D., Csernansky J. When symptoms persist: clozapine augmentation strategies. Schizophr. Bull. 2001, 27:615-628.
2. Fleischhacker W.W., Heikkinen M.E., Olié J.P., Landsberg W., Dewaele P., McQuade R.D., Loze J.Y., Hennicken D., Kerselaers W. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010, 13:1115-1125.
3. Freudenreich O., Henderson D.C., Walsh J.P., Culhane M.A., Goff D.C. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr. Res. 2007, 92:90-94.
4. Friedman J., Ault K., Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol. Psychiatry 1997, 42:522-523.
5. Friedman J.I., Lindenmayer J.P., Alcantara F., Bowler S., Parak M., White L., Iskander A., Parrella M., Adler D.N., Tsopelas N.D., Tsai W.Y., Novakovic V., Novakovick V., Harvey P.D., Davis K.L., Kaushik S. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 2011, 36:1289-1295.
6. Gould R.J., Murphy K.M., Reynolds I.J., Snyder S.H. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:5122-5125.
7. Honer W.G., Thornton A.E., Chen E.Y., Chan R.C., Wong J.O., Bergmann A., Falkai P., Pomarol-Clotet E., McKenna P.J., Stip E., Williams R., MacEwan G.W., Wasan K., Procyshyn R., Group, C.a.R.E.C.S. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med. 2006, 354:472-482.
8. Kane J.M., Marder S.R., Schooler N.R., Wirshing W.C., Umbricht D., Baker R.W., Wirshing D.A., Safferman A., Ganguli R., McMeniman M., Borenstein M. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry 2001, 58:965-972.
9. Kronig M.H., Munne R.A., Szymanski S., Safferman A.Z., Pollack S., Cooper T., Kane J.M., Lieberman J.A. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am. J. Psychiatry 1995, 152:179-182.
10. Opler L.A., Feinberg S.S. The role of pimozide in clinical psychiatry: a review. J. Clin. Psychiatry 1991, 52:221-233.
11. Peacock L., Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J. Clin. Psychiatry 1994, 55:44-49.
12. Perry P.J., Miller D.D., Arndt S.V., Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiatry 1991, 148:231-235.
13. Potkin S.G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychiatry 1994, 55(Suppl. B):133-136.
14. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 1997, 337:809-815.
15. Sallee F.R., Sethuraman G., Rock C.M. Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta Psychiatr. Scand. 1994, 90:4-9.
16. Shiloh R., Zemishlany Z., Aizenberg D., Radwan M., Schwartz B., Dorfman-Etrog P., Modai I., Khaikin M., Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br. J. Psychiatry 1997, 171:569-573.